Atlas Trials

Dong sheng Zhang

1 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Dong sheng Zhang

RecordFirmDate
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy (NCT07397819)Dong sheng Zhang2025-11-28

Track Dong sheng Zhang automatically

Every clearance here is in the API, with alerts when new ones post.